12-Month Outcomes of MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Safety, Efficacy, and Quality of Life

This prospective phase 2 study evaluated the safety, efficacy, and quality of life outcomes of MRI-guided transurethral ultrasound ablation (TULSA) for localized prostate cancer (PCa). A total of 60 men with clinically significant PCa received either whole-gland or focal TULSA. The study found a low incidence of adverse events, with 70% of patients free of in-field clinically significant PCa at one-year post-treatment. PSA levels decreased significantly, and most patients demonstrated stable urinary function. However, some reported a decline in sexual function. Overall, TULSA proved to be a safe and effective treatment option with minimal impact on quality of life.